ATC Group: N07XX12 Patisiran

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N07XX12 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N07 Other nervous system drugs
3 N07X Other nervous system drugs
4 N07XX Other nervous system drugs
5 N07XX12

Active ingredients in N07XX12

Active Ingredient Description
Patisiran

Patisiran is a double-stranded small interfering ribonucleic acid (siRNA) that specifically targets a genetically conserved sequence in the 3’ untranslated region of all mutant and wild-type TTR mRNA. Through a natural process called RNA interference (RNAi), patisiran causes the catalytic degradation of TTR mRNA in the liver, resulting in a reduction of serum TTR protein, a carrier of retinol binding protein which facilitates transport of vitamin A in the blood.

Related product monographs

Title Information Source Document Type  
ONPATTRO Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Romania (RO)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.